These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 9580110)

  • 1. Human apolipoprotein A-II is a pro-atherogenic molecule when it is expressed in transgenic mice at a level similar to that in humans: evidence of a potentially relevant species-specific interaction with diet.
    Escolà-Gil JC; Marzal-Casacuberta A; Julve-Gil J; Ishida BY; Ordóñez-Llanos J; Chan L; González-Sastre F; Blanco-Vaca F
    J Lipid Res; 1998 Feb; 39(2):457-62. PubMed ID: 9580110
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Decreased susceptibility to diet-induced atherosclerosis in human apolipoprotein A-II transgenic mice.
    Tailleux A; Bouly M; Luc G; Castro G; Caillaud JM; Hennuyer N; Poulain P; Fruchart JC; Duverger N; Fiévet C
    Arterioscler Thromb Vasc Biol; 2000 Nov; 20(11):2453-8. PubMed ID: 11073852
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Functional lecithin:cholesterol acyltransferase deficiency and high density lipoprotein deficiency in transgenic mice overexpressing human apolipoprotein A-II.
    Marzal-Casacuberta A; Blanco-Vaca F; Ishida BY; Julve-Gil J; Shen J; Calvet-Márquez S; González-Sastre F; Chan L
    J Biol Chem; 1996 Mar; 271(12):6720-8. PubMed ID: 8636092
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Overexpression of human apolipoprotein A-II in transgenic mice does not impair macrophage-specific reverse cholesterol transport in vivo.
    Rotllan N; Ribas V; Calpe-Berdiel L; Martín-Campos JM; Blanco-Vaca F; Escolà-Gil JC
    Arterioscler Thromb Vasc Biol; 2005 Sep; 25(9):e128-32. PubMed ID: 15994442
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vivo interactions of apoA-II, apoA-I, and hepatic lipase contributing to HDL structure and antiatherogenic functions.
    Hedrick CC; Castellani LW; Wong H; Lusis AJ
    J Lipid Res; 2001 Apr; 42(4):563-70. PubMed ID: 11290828
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human apolipoprotein A-II enrichment displaces paraoxonase from HDL and impairs its antioxidant properties: a new mechanism linking HDL protein composition and antiatherogenic potential.
    Ribas V; Sánchez-Quesada JL; Antón R; Camacho M; Julve J; Escolà-Gil JC; Vila L; Ordóñez-Llanos J; Blanco-Vaca F
    Circ Res; 2004 Oct; 95(8):789-97. PubMed ID: 15388641
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ApoA-II expression in CETP transgenic mice increases VLDL production and impairs VLDL clearance.
    Escolà-Gil JC; Julve J; Marzal-Casacuberta A; Ordóñez-Llanos J; González-Sastre F; Blanco-Vaca F
    J Lipid Res; 2001 Feb; 42(2):241-8. PubMed ID: 11181754
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of human lecithin-cholesterol acyltransferase in transgenic mice. Effect of human apolipoprotein AI and human apolipoprotein all on plasma lipoprotein cholesterol metabolism.
    Francone OL; Gong EL; Ng DS; Fielding CJ; Rubin EM
    J Clin Invest; 1995 Sep; 96(3):1440-8. PubMed ID: 7657816
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High density lipoprotein particle size restriction in apolipoprotein A-I(Milano) transgenic mice.
    Bielicki JK; Forte TM; McCall MR; Stoltzfus LJ; Chiesa G; Sirtori CR; Franceschini G; Rubin EM
    J Lipid Res; 1997 Nov; 38(11):2314-21. PubMed ID: 9392429
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transgenic mice expressing high levels of human apolipoprotein B develop severe atherosclerotic lesions in response to a high-fat diet.
    Purcell-Huynh DA; Farese RV; Johnson DF; Flynn LM; Pierotti V; Newland DL; Linton MF; Sanan DA; Young SG
    J Clin Invest; 1995 May; 95(5):2246-57. PubMed ID: 7738190
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Atherosclerosis in transgenic mice overexpressing apolipoprotein A-II.
    Warden CH; Hedrick CC; Qiao JH; Castellani LW; Lusis AJ
    Science; 1993 Jul; 261(5120):469-72. PubMed ID: 8332912
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reduced aortic lesions and elevated high density lipoprotein levels in transgenic mice overexpressing mouse apolipoprotein A-IV.
    Cohen RD; Castellani LW; Qiao JH; Van Lenten BJ; Lusis AJ; Reue K
    J Clin Invest; 1997 Apr; 99(8):1906-16. PubMed ID: 9109435
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protein composition determines the anti-atherogenic properties of HDL in transgenic mice.
    Schultz JR; Verstuyft JG; Gong EL; Nichols AV; Rubin EM
    Nature; 1993 Oct; 365(6448):762-4. PubMed ID: 8413656
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Free cholesterol deposition in the cornea of human apolipoprotein A-II transgenic mice with functional lecithin: cholesterol acyltransferase deficiency.
    Julve-Gil J; Ruiz-Pérez E; Casaroli-Marano RP; Marzal-Casacuberta A; Escolà-Gil JC; González-Sastre F; Blanco-Vaca F
    Metabolism; 1999 Apr; 48(4):415-21. PubMed ID: 10206431
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transgenic overexpression of human lecithin: cholesterol acyltransferase (LCAT) in mice does not increase aortic cholesterol deposition.
    Furbee JW; Parks JS
    Atherosclerosis; 2002 Nov; 165(1):89-100. PubMed ID: 12208474
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human ApoA-II inhibits the hydrolysis of HDL triglyceride and the decrease of HDL size induced by hypertriglyceridemia and cholesteryl ester transfer protein in transgenic mice.
    Zhong S; Goldberg IJ; Bruce C; Rubin E; Breslow JL; Tall A
    J Clin Invest; 1994 Dec; 94(6):2457-67. PubMed ID: 7989603
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Apolipoprotein A-II, HDL metabolism and atherosclerosis.
    Tailleux A; Duriez P; Fruchart JC; Clavey V
    Atherosclerosis; 2002 Sep; 164(1):1-13. PubMed ID: 12119188
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ApoA-I deficiency causes both hypertriglyceridemia and increased atherosclerosis in human apoB transgenic mice.
    Voyiaziakis E; Goldberg IJ; Plump AS; Rubin EM; Breslow JL; Huang LS
    J Lipid Res; 1998 Feb; 39(2):313-21. PubMed ID: 9507992
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Short-term feeding of atherogenic diet to mice results in reduction of HDL and paraoxonase that may be mediated by an immune mechanism.
    Hedrick CC; Hassan K; Hough GP; Yoo JH; Simzar S; Quinto CR; Kim SM; Dooley A; Langi S; Hama SY; Navab M; Witztum JL; Fogelman AM
    Arterioscler Thromb Vasc Biol; 2000 Aug; 20(8):1946-52. PubMed ID: 10938016
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Human apolipoprotein A-I prevents atherosclerosis associated with apolipoprotein[a] in transgenic mice.
    Liu AC; Lawn RM; Verstuyft JG; Rubin EM
    J Lipid Res; 1994 Dec; 35(12):2263-7. PubMed ID: 7897323
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.